- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07839221
Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis
The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are Lung Ultrasound and a blood marker called Growth Differentiation Factor-15 (GDF-15).
The main question it aims to answer is:
Does the combination of these 2 modalities have the diagnostic accuracy similar to the gold standard test which is High Resolution Computed Tomography (HRCT) of the Lungs? Does this combination have the potential to become a validated screening tool?
Participants will be in 2 groups: the RA group and the SSc group, each will have the diagnostic combination and a reference HRCT for comparison of results.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Interstitial lung disease (ILD) represents one of the most severe extra-articular and systemic manifestations of Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc). ILD significantly increases morbidity and remains a leading cause of mortality in both disease entities.
Accumulating evidence demonstrates a high prevalence of subclinical interstitial lung disease, occurring in up to 33% of patients with rheumatoid arthritis and 50% of patients with systemic sclerosis. Therefore, Early detection during this subclinical window is paramount to initiate timely immunomodulatory or antifibrotic therapies before irreversible fibrotic replacement occurs.
Although high-resolution computed tomography (HRCT) of the chest remains the gold standard for diagnosing interstitial lung disease, its high cost and associated radiation exposure restrict its utility as a routine screening tool for all patients, particularly in resource-limited settings. Consequently, there is a clinical demand for a validated, non-invasive, radiation-free, and cost-effective triage tool to screen populations at risk and identify those who genuinely require diagnostic HRCT evaluation.
Growth Differentiation Factor-15 (GDF-15), a stress-responsive cytokine belonging to the Transforming Growth Factor-beta (TGF-β) superfamily, has emerged as a novel systemic biomarker reflective of cellular stress, inflammation, and fibrogenesis . GDF-15 is significantly elevated in active systemic autoimmune conditions such as Behcet disease, Inflammatory bowel disease and Sjogren's disease . Importantly, GDF-15 is overexpressed in pulmonary epithelial cells during active fibrogenesis and serves as a key circulating biomarker in idiopathic pulmonary fibrosis as well as connective tissue disease-associated ILD and pulmonary hypertension.
As a cellular stress cytokine, serum GDF-15 reflects the distinct pathogenetic mechanisms driving ILD in each condition:
RA-ILD: Mucosal citrullination and anti-CCP immune complex deposition 2022induce alveolar epithelial injury and inflammatory cytokine release. Here, elevated GDF-15 primarily reflects acute epithelial stress and immune-mediated inflammatory intensity.
SSc-ILD: Microvascular damage and endothelial apoptosis trigger TGF-β signaling and myofibroblast expansion. Here, GDF-15 acts downstream of TGF-β, reflecting chronic endothelial ischemia and fibrogenesis.
Concurrently, point-of-care Lung Ultrasound (LUS) has revolutionized bedside assessment in rheumatology. LUS detects interstitial pulmonary changes-specifically B-lines and pleural line irregularities-with exceptional sensitivity. Recent evidence highlights that LUS achieves remarkable diagnostic accuracy compared to HRCT in both RA-ILD and SSc-ILD.
While GDF-15 reflects early molecular and cellular fibrotic activity and LUS identifies early structural lung affection, whether combining these two non-invasive modalities yields superior diagnostic accuracy for subclinical ILD screening compared to either modality alone remains unexplored. Combining a molecular circulating marker with a physical point-of-care imaging tool could establish a robust triage model for outpatient rheumatology clinics. Therefore, this is a diagnostic accuracy study to determine the outcomes of this combination.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sara Taher Amin, Assistant lecturer
- Número de teléfono: 00201111337547
- Correo electrónico: sarataher.md@gmail.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
All adult patients diagnosed as RA "according to 2010 ACR/EULAR classification criteria" or SSc "according to 2013 ACR/EULAR classification criteria", either known to be complicated with ILD or not, are recruited from inpatient and outpatient clinic of Rheumatology and Rehabilitation department of Assiut University hospital
Descripción
Inclusion Criteria:
1- Adult patients (≥18 years) with confirmed diagnosis of RA or SSc.
Exclusion Criteria:
- Active respiratory tract infection or acute exacerbation of pulmonary disease.
- Other causes of pulmonary fibrosis such as history of heavy smoking (>15 pack-years) or significant environmental/occupational exposure known to induce pulmonary fibrosis.
- Pre-existing primary chronic lung diseases (e.g., COPD, bronchial asthma, active tuberculosis, severe bronchiectasis).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: CROSS_SECTIONAL
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Rheumatoid arthritis patients
Either known to have ILD or not, Asymptomatic patients |
Lung Ultrasound, 14 point protocol Serum sample will be collected and ELISA test will be conducted High resolution CT of the lungs |
|
Systemic Sclerosis patients
Either known to have ILD or not, Asymptomatic patients |
Lung Ultrasound, 14 point protocol Serum sample will be collected and ELISA test will be conducted High resolution CT of the lungs |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Determine the overall diagnostic accuracy (Sensitivity, Specificity, positive and negative predictive values) of combined GDF-15 + LUS compared to HRCT in screening for subclinical ILD in RA and SSc patients.
Periodo de tiempo: Baseline
|
All patients will undergo combined GDF-15 + LUS to determine their diagnostic accuracy |
Baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Compare baseline serum GDF-15 levels between RA-ILD and SSc-ILD cohorts to assess whether differing underlying pathogenetic mechanisms influence circulating GDF-15 concentrations and its diagnostic cut-off values.
Periodo de tiempo: Baseline
|
Cut-off values of GDF-15 will be determined for each group |
Baseline
|
|
Evaluate the correlation between serum GDF-15 levels and the structural extent/severity of ILD on HRCT.
Periodo de tiempo: Baseline
|
Level of GDF-15 will be correlated with CT findings |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Essam Ahmed Abda, Professor, Professor of Rheumatology, Rehabilitation and Physical medicine
- Director de estudio: Mohammed Raouf Abd El-razik, Assistant Professor, Assistant professor of Rheumatology, Rehabilitation and physical medicine
- Director de estudio: Amira Mostafa El-Sonbaty, Lecturer, Lecturer of Rheumatology, Rehabilitation and Physical medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Procesos Patológicos
- Artritis
- Enfermedades Articulares
- Enfermedades reumáticas
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Enfermedades de la piel
- Fibrosis
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Fibrosis pulmonar
- Enfermedades Pulmonares Intersticiales
- Esclerodermia Sistémica
- Artritis Reumatoide
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Tomografía
- Imágenes de diagnóstico
- Radiografía
- Interpretación de imágenes, asistida por computadora
- Mejora de la imagen radiográfica
- Mejora de la imagen
- Fotografía
- Tomografía, rayos X
- Tomografía, rayos X calculados
Otros números de identificación del estudio
- PhD Rheumatology thesis
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .